Shallow whole-genome sequencing: a useful, easy to apply molecular technique for CNA detection on FFPE tumor tissue-a glioma-driven study.


Journal

Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 16 08 2021
accepted: 03 01 2022
revised: 10 12 2021
pubmed: 17 1 2022
medline: 12 4 2022
entrez: 16 1 2022
Statut: ppublish

Résumé

Copy number alterations (CNAs) have increasingly become part of the diagnostic algorithm of glial tumors. Alterations such as homozygous deletion of CDKN2A/B, 7 +/ 10 - chromosome copy number changes or EGFR amplification are predictive of a poor prognosis. The codeletion of chromosome arms 1p and 19q, typically associated with oligodendroglioma, implies a more favorable prognosis. Detection of this codeletion by the current diagnostic standard, being fluorescence in situ hybridization (FISH), is sometimes however subject to technical and interpretation problems. In this study, we evaluated CNA detection by shallow whole-genome sequencing (sWGS) as an inexpensive, complementary molecular technique. A cohort of 36 glioma tissue samples, enriched with "difficult" and "ambiguous" cases, was analyzed by sWGS. sWGS results were compared with FISH assays of chromosomes 1p and 19q. In addition, CNAs relevant to glioblastoma diagnosis were explored. In 4/36 samples, EGFR (7p11.2) amplifications and homozygous loss of CDKN2A/B were identified by sWGS. Six out of 8 IDH-wild-type glioblastomas demonstrated a prognostic chromosome 7/chromosome 10 signature. In 11/36 samples, local interstitial and terminal 1p/19q alterations were detected by sWGS, implying that FISH's targeted nature might promote false arm-level extrapolations. In this cohort, differences in overall survival between patients with and without codeletion were better pronounced by the sequencing-based distinction (likelihood ratio of 7.48) in comparison to FISH groupings (likelihood ratio of 0.97 at diagnosis and 1.79 ± 0.62 at reobservation), suggesting sWGS is more accurate than FISH. We recognized adverse effects of tissue block age on FISH signals. In addition, we show how sWGS reveals relevant aberrations beyond the 1p/19q state, such as EGFR amplification, combined gain of chromosome 7 and loss of chromosome 10, and homozygous loss of CDKN2A/B. The findings presented by this study might stimulate implementation of sWGS as a complementary, easy to apply technique for copy number detection.

Identifiants

pubmed: 35034191
doi: 10.1007/s00428-022-03268-w
pii: 10.1007/s00428-022-03268-w
doi:

Substances chimiques

Isocitrate Dehydrogenase EC 1.1.1.41
ErbB Receptors EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

677-686

Subventions

Organisme : Bijzonder Onderzoeksfonds
ID : BOF.STA.2017.0002.01

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Louis DN OH, Wiestler OD, Cavenee WK (2016) World Health Organization histological classification of tumours of the central nervous system., International Agency for Research on Cancer, France
Gelpi E, Ambros IM, Birner P, Luegmayr A, Drlicek M, Fischer I, Kleinert R, Maier H, Huemer M, Gatterbauer B, Anton J, Rossler K, Budka H, Ambros PF, Hainfellner JA (2003) Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens. Mod Pathol 16:708–715. https://doi.org/10.1097/01.Mp.0000076981.90281.Bf
doi: 10.1097/01.Mp.0000076981.90281.Bf pubmed: 12861068
Wesseling P, van den Bent M, Perry A (2015) Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol 129:809–827. https://doi.org/10.1007/s00401-015-1424-1
doi: 10.1007/s00401-015-1424-1 pubmed: 25943885 pmcid: 4436696
Horbinski C, Miller CR, Perry A (2011) Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade. Brain pathology (Zurich, Switzerland) 21:57–73. https://doi.org/10.1111/j.1750-3639.2010.00453.x
doi: 10.1111/j.1750-3639.2010.00453.x
Sim J, Nam DH, Kim Y, Lee IH, Choi JW, Sa JK, Suh YL (2018) Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization. Med Oncol (Northwood, London, England) 35:60. https://doi.org/10.1007/s12032-018-1119-2
doi: 10.1007/s12032-018-1119-2
Woehrer A, Sander P, Haberler C, Kern S, Maier H, Preusser M, Hartmann C, Kros JM, Hainfellner JA (2011) FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice – a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies. Clinl Neuropathol 30:47–55. https://doi.org/10.5414/npp30047
doi: 10.5414/npp30047
Burger PC, Minn AY, Smith JS, Borell TJ, Jedlicka AE, Huntley BK, Goldthwaite PT, Jenkins RB, Feuerstein BG (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 14(9):842–853. https://doi.org/10.1038/modpathol.3880400
Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, Giangaspero F, Giannini C, Mokhtari K, Mørk SJ, Paetau A, Reifenberger G, van den Bent MJ (2007) Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 66(6):545–551. https://doi.org/10.1097/01.jnen.0000263869.84188.72
doi: 10.1097/01.jnen.0000263869.84188.72 pubmed: 17549014
Franco-Hernandez C, Martinez-Glez V, de Campos JM, Isla A, Vaquero J, Gutierrez M, Casartelli C, Rey JA (2009) Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity. Cancer Genet Cytogenet 190:93–96. https://doi.org/10.1016/j.cancergencyto.2008.09.017
doi: 10.1016/j.cancergencyto.2008.09.017 pubmed: 19380026
Chaturbedi A, Yu L, Linskey ME, Zhou YH (2012) Detection of 1p19q deletion by real-time comparative quantitative PCR. Biomark Insights 7:9–17. https://doi.org/10.4137/bmi.S9003
doi: 10.4137/bmi.S9003 pubmed: 22403483 pmcid: 3290106
Jaunmuktane Z, Capper D, Jones DTW, Schrimpf D, Sill M, Dutt M, Suraweera N, Pfister SM, von Deimling A, Brandner S (2019) Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. Acta Neuropathologica Communications 7:24. https://doi.org/10.1186/s40478-019-0668-8
doi: 10.1186/s40478-019-0668-8 pubmed: 30786920 pmcid: 6381711
Dubbink HJ, Atmodimedjo PN, van Marion R, Krol NMG, Riegman PHJ, Kros JM, van den Bent MJ, Dinjens WNM (2016) Diagnostic detection of allelic losses and imbalances by next-generation sequencing: 1p/19q co-deletion analysis of gliomas. J Mol Diagn 18:775–786. https://doi.org/10.1016/j.jmoldx.2016.06.002
doi: 10.1016/j.jmoldx.2016.06.002 pubmed: 27461031
Duval C, de Tayrac M, Michaud K, Cabillic F, Paquet C, Gould PV, Saikali S (2015) Automated analysis of 1p/19q status by FISH in oligodendroglial tumors: rationale and proposal of an algorithm. PloS one 10:e0132125. https://doi.org/10.1371/journal.pone.0132125
doi: 10.1371/journal.pone.0132125 pubmed: 26135922 pmcid: 4489714
Pinkham MB, Telford N, Whitfield GA, Colaco RJ, O’Neill F, McBain CA (2015) FISHing tips: what every clinician should know about 1p19q analysis in gliomas using fluorescence in situ hybridisation. Clin Oncol (R Coll Radiol (Great Britain)) 27:445–453. https://doi.org/10.1016/j.clon.2015.04.008
doi: 10.1016/j.clon.2015.04.008
Reddy KS (2008) Assessment of 1p/19q deletions by fluorescence in situ hybridization in gliomas. Cancer Genet Cytogenet 184:77–86. https://doi.org/10.1016/j.cancergencyto.2008.03.009
doi: 10.1016/j.cancergencyto.2008.03.009 pubmed: 18617055
Raman L, Baetens M, De Smet M, Dheedene A, Van Dorpe J, Menten B (2019) PREFACE: in silico pipeline for accurate cell-free fetal DNA fraction prediction. Prenat Diagn 39:925–933. https://doi.org/10.1002/pd.5508
doi: 10.1002/pd.5508 pubmed: 31219182 pmcid: 6771918
Van der Linden M, Raman L, Vander Trappen A, Dheedene A, De Smet M, Sante T, Creytens D, Lievens Y, Menten B, Van Dorpe J, Van Roy N (2019) Detection of copy number alterations by shallow whole-genome sequencing of formalin-fixed, paraffin-embedded tumor tissue. Arch Pathol Lab Med 144:974–981. https://doi.org/10.5858/arpa.2019-0010-OA
doi: 10.5858/arpa.2019-0010-OA
Ambros PF, Ambros IM (2001) Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37:492–504. https://doi.org/10.1002/mpo.1242
doi: 10.1002/mpo.1242 pubmed: 11745887
Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, Mokhtari K, van Duinen SG, Teepen JL, Wesseling P, Vandenbos F, Grisold W, Sipos L, Mirimanoff R, Vecht CJ, Allgeier A, Lacombe D, van den Bent MJ (2009) Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro Oncol 11:737–746. https://doi.org/10.1215/15228517-2009-011
doi: 10.1215/15228517-2009-011 pubmed: 19224764 pmcid: 2802394
Raman L, Van der Linden M, Van der Eecken K, Vermaelen K, Demedts I, Surmont V, Himpe U, Dedeurwaerdere F, Ferdinande L, Lievens Y, Claes K, Menten B, Van Dorpe J (2020) Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma. Genome Medicine 12:35. https://doi.org/10.1186/s13073-020-00735-4
doi: 10.1186/s13073-020-00735-4 pubmed: 32317009 pmcid: 7175544
Langmead B, Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. Nat Methods 9:357–359. https://doi.org/10.1038/nmeth.1923
doi: 10.1038/nmeth.1923 pubmed: 22388286 pmcid: 3322381
Tischler G, Leonard S (2014) biobambam: tools for read pair collation based algorithms on BAM files. Source Code Biol Med 9:13. https://doi.org/10.1186/1751-0473-9-13
doi: 10.1186/1751-0473-9-13 pmcid: 4075596
Raman L (2019) WisecondorX: improved copy number detection for routine shallow whole-genome sequencing. Nucleic Acids Res 47(4):1605–1614
doi: 10.1093/nar/gky1263 pubmed: 30566647
Olshen AB, Venkatraman ES, Lucito R, Wigler M (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5:557–572. https://doi.org/10.1093/biostatistics/kxh008
doi: 10.1093/biostatistics/kxh008 pubmed: 15475419
Stichel D, Ebrahimi A, Reuss D, Schrimpf D, Ono T, Shirahata M, Reifenberger G, Weller M, Hänggi D, Wick W, Herold-Mende C, Westphal M, Brandner S, Pfister SM, Capper D, Sahm F, von Deimling A (2018) Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136:793–803. https://doi.org/10.1007/s00401-018-1905-0
doi: 10.1007/s00401-018-1905-0 pubmed: 30187121
Jones DT, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K, Collins VP (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Can Res 68:8673–8677. https://doi.org/10.1158/0008-5472.Can-08-2097
doi: 10.1158/0008-5472.Can-08-2097
Duval C, de Tayrac M, Sanschagrin F, Michaud K, Gould PV, Saikali S (2014) ImmunoFISH is a reliable technique for the assessment of 1p and 19q status in oligodendrogliomas. PloS one 9:e100342. https://doi.org/10.1371/journal.pone.0100342
doi: 10.1371/journal.pone.0100342 pubmed: 24949947 pmcid: 4065070

Auteurs

Kim Van der Eecken (K)

Department of Pathology, Ghent University, Ghent University Hospital, Ghent, Belgium.
Cancer Research Institute (CRIG), Ghent, Belgium.

Malaïka Van der Linden (M)

Department of Pathology, Ghent University, Ghent University Hospital, Ghent, Belgium.
Cancer Research Institute (CRIG), Ghent, Belgium.
Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, Ghent University Hospital, Ghent, Belgium.

Lennart Raman (L)

Department of Pathology, Ghent University, Ghent University Hospital, Ghent, Belgium.
Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, Ghent University Hospital, Ghent, Belgium.

David Creytens (D)

Department of Pathology, Ghent University, Ghent University Hospital, Ghent, Belgium.
Cancer Research Institute (CRIG), Ghent, Belgium.

Franceska Dedeurwaerdere (F)

Department of Pathology, AZ Delta, Roeselare, Belgium.

Koen De Winne (K)

Department of Pathology, Antwerp University Hospital, Antwerp, Belgium.

Liesbeth Ferdinande (L)

Department of Pathology, Ghent University, Ghent University Hospital, Ghent, Belgium.
Cancer Research Institute (CRIG), Ghent, Belgium.

Martin Lammens (M)

Department of Pathology, Antwerp University Hospital, Antwerp, Belgium.

Björn Menten (B)

Cancer Research Institute (CRIG), Ghent, Belgium.
Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, Ghent University Hospital, Ghent, Belgium.

Isabelle Rottiers (I)

Department of Pathology, Ghent University, Ghent University Hospital, Ghent, Belgium.
Cancer Research Institute (CRIG), Ghent, Belgium.

Bram Van Gaever (B)

Department of Pathology, Ghent University, Ghent University Hospital, Ghent, Belgium.

Caroline Van den Broecke (C)

Department of Pathology, AZ Sint-Lucas, Ghent, Belgium.

Koen Van de Vijver (K)

Department of Pathology, Ghent University, Ghent University Hospital, Ghent, Belgium.
Cancer Research Institute (CRIG), Ghent, Belgium.

Nadine Van Roy (N)

Cancer Research Institute (CRIG), Ghent, Belgium.
Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, Ghent University Hospital, Ghent, Belgium.

Sofie Verbeke (S)

Department of Pathology, Ghent University, Ghent University Hospital, Ghent, Belgium.
Cancer Research Institute (CRIG), Ghent, Belgium.

Jo Van Dorpe (J)

Department of Pathology, Ghent University, Ghent University Hospital, Ghent, Belgium. jo.vandorpe@uzgent.be.
Cancer Research Institute (CRIG), Ghent, Belgium. jo.vandorpe@uzgent.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH